SFU
ACAD icon

Stonehage Fleming (UK)’s Acadia Pharmaceuticals ACAD Stock Holding History

Stonehage Fleming (UK)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,894
Closed -$46K – 261
2014
Q1 		$46K Sell
1,894
-931
-33% -$23.6K 0.02% 260
2013
Q4 		$71K Buy
+2,825
New +$66.6K 0.03% 190

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Stonehage Fleming (UK)'s ACAD Position: Q2 2014 in Review

Stonehage Fleming (UK) sold out of Acadia Pharmaceuticals (ACAD) in Q2 2014, closing a stake of 1,894 shares — an estimated $46K sold.

Stonehage Fleming (UK) first reported a position in ACAD in Q4 2013 and held it in 2 quarters. The position peaked at $71K in Q4 2013. 160 funds tracked by Wall St. Rank hold ACAD as of Q2 2014.

  • Stonehage Fleming (UK) reported no remaining Acadia Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Stonehage Fleming (UK) sold 1,894 Acadia Pharmaceuticals shares in Q2 2014, an estimated $46K.
  • Stonehage Fleming (UK) first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Stonehage Fleming (UK)'s Acadia Pharmaceuticals position peaked at $71K in Q4 2013.
  • 160 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2014.

Based on Stonehage Fleming (UK)'s 13F filing for Q2 2014, filed 11 Oct 2019.